Genomics of Adverse Drug Reactions

被引：43
作者：
Alfirevic, Ana [1 ]
Pirmohamed, Munir [1 ]
机构：
[1] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2017年 / 38卷 / 01期
基金：
欧盟地平线“2020”; 美国国家卫生研究院; 英国医学研究理事会;
关键词：
INDUCED LIVER-INJURY; IMPLEMENTATION CONSORTIUM GUIDELINES; HLA-B GENOTYPE; HUMAN-LEUKOCYTE ANTIGEN-B-ASTERISK-5701; ANTHRACYCLINE-INDUCED CARDIOTOXICITY; ABACAVIR HYPERSENSITIVITY; IMPAIRED OXIDATION; PEPTIDE REPERTOIRE; PRECISION MEDICINE; COST-EFFECTIVENESS;
D O I：
10.1016/j.tips.2016.11.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Adverse drug reactions (ADRs) are common, are associated with morbidity and mortality, and are costly to healthcare systems. Genomic factors predispose to ADRs, but these vary depending on the drug, patient, and disease. Genomic testing can not only help to predict and prevent ADRs but can also be used in other ways (diagnosis, closer monitoring of those at risk, pre-emptive genotyping, and understanding of mechanism), all of which will be important in the future to improve the benefit-risk ratio of drugs. In the era of precision medicine, such genomic data will need to be integrated with other forms of data to develop a comprehensive and integrated approach to improve responses to medicines used in patients.
引用
收藏
页码：100 / 109
页数：10
相关论文
共 79 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Predictive Genetic Testing for Drug-Induced Liver Injury: Considerations of Clinical Utility
    Alfirevic, A.
    Pirmohamed, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) : 376 - 380
  • [3] A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
    Aminkeng, Folefac
    Bhavsar, Amit P.
    Visscher, Henk
    Rassekh, Shahrad R.
    Li, Yuling
    Lee, Jong W.
    Brunham, Liam R.
    Caron, Huib N.
    van Dalen, Elvira C.
    Kremer, Leontien C.
    van der Pal, Helena J.
    Amstutz, Ursula
    Rieder, Michael J.
    Bernstein, Daniel
    Carleton, Bruce C.
    Hayden, Michael R.
    Ross, Colin J. D.
    [J]. NATURE GENETICS, 2015, 47 (09) : 1079 - +
  • [4] Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status
    Barclay, ML
    Sawyers, SM
    Begg, EJ
    Zhang, M
    Roberts, RL
    Kennedy, MA
    Elliott, JM
    [J]. PHARMACOGENETICS, 2003, 13 (10): : 627 - 632
  • [5] Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics
    Becquemont, Laurent
    Alfrieve, Ana
    Amstutz, Ursula
    Brauch, Hiltrud
    Jacqz-Algrain, Evelyne
    Laurent-Puig, Pierre
    Molina, Miguel A.
    Niemi, Mikko
    Schwab, Matthias
    Somogyi, Andrew A.
    Thervet, Eric
    Maitland-van der Zee, Anke Hilse
    van Kuilenburg, Andre B. P.
    van Schaik, Ron H. N.
    Verstuyft, Celine
    Wadelius, Mia
    Daly, Ann K.
    [J]. PHARMACOGENOMICS, 2011, 12 (01) : 113 - 124
  • [6] Bjomsson E. S., 2013, GASTROENTEROLOGY, V144, P1419
  • [7] The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy
    Brixner, D.
    Biltaji, E.
    Bress, A.
    Unni, S.
    Ye, X.
    Mamiya, T.
    Ashcraft, K.
    Biskupiak, J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 213 - 228
  • [8] Systems biology approaches to adverse drug effects: the example of cardio-oncology
    Brown, Sherry-Ann
    Sandhu, Nicole
    Herrmann, Joerg
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (12) : 718 - 731
  • [9] Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
    Chen, Pei
    Lin, Juei-Jueng
    Lu, Chin-Song
    Ong, Cheung-Ter
    Hsieh, Peiyuan F.
    Yang, Chih-Chao
    Tai, Chih-Ta
    Wu, Shey-Lin
    Lu, Cheng-Hsien
    Hsu, Yung-Chu
    Yu, Hsiang-Yu
    Ro, Long-Sun
    Lu, Chung-Ta
    Chu, Chun-Che
    Tsai, Jing-Jane
    Su, Yu-Hsiang
    Lan, Sheng-Hsing
    Sung, Sheng-Feng
    Lin, Shu-Yi
    Chuang, Hui-Ping
    Huang, Li-Chen
    Chen, Ying-Ju
    Tsai, Pei-Joung
    Liao, Hung-Ting
    Lin, Yu-Hsuan
    Chen, Chien-Hsiun
    Chung, Wen-Hung
    Hung, Shuen-Iu
    Wu, Jer-Yuarn
    Chang, Chi-Feng
    Chen, Luke
    Chen, Yuan-Tsong
    Shen, Chen-Yang
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) : 1126 - 1133
  • [10] Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions
    Chen, Zhibin
    Liew, Danny
    Kwan, Patrick
    [J]. NEUROLOGY, 2014, 83 (22) : 2077 - 2084
12345678